Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.

Item
http://www.wikidata.org/entity/Q34452673
Combinations in multimodality treatments and clinical outcomes during cancerContinuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer.Use of bevacizumab as a first-line treatment for metastatic breast cancer.Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer.Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review.A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute.Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study
P2860

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.

Item
http://www.wikidata.org/entity/Q34452673
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Maintenance bevacizumab beyond ...... ination with hormonal therapy.
@ast
Maintenance bevacizumab beyond ...... ination with hormonal therapy.
@en
Maintenance bevacizumab beyond ...... ination with hormonal therapy.
@nl
type
label
Maintenance bevacizumab beyond ...... ination with hormonal therapy.
@ast
Maintenance bevacizumab beyond ...... ination with hormonal therapy.
@en
Maintenance bevacizumab beyond ...... ination with hormonal therapy.
@nl
prefLabel
Maintenance bevacizumab beyond ...... ination with hormonal therapy.
@ast
Maintenance bevacizumab beyond ...... ination with hormonal therapy.
@en
Maintenance bevacizumab beyond ...... ination with hormonal therapy.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Maintenance bevacizumab beyond ...... ination with hormonal therapy.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P478
P50
P577
P5875
P6179
P698
P921
P932